Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum CRISPR Therapeutics AG CRSP

Healthcare Biotechnology
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this... see more

Bullboard (NDAQ:CRSP)

View:
Post by MikeTesteron Aug 02, 2024 3:54pm

CRISPR Therapeutics AG (NASDAQ:CRSP): A Pioneering Gene Edit

https://beyondspx.com/2024/07/31/crispr-therapeutics-ag-nasdaqcrsp-a-pioneering-gene-editing-company-poised-for-continued-growth/
48
Comment by CreatingApeon May 08, 2024 7:01pm

RE:regrets

Lol if you think it's a 1000 dollar stock it's definitely not too late. 52.22 at close today...
26
Discussion
Post by whytestockson Feb 19, 2024 2:00am

If You Invested $10,000 in CRISPR Therapeutics in 2019, This

NEWS: $CRSP If You Invested $10,000 in CRISPR Therapeutics in 2019, This Is How Much You Would Have Today2024-02-19 01:45:00 ET Companies in the biotech industry are often capable of delivering ...more  
193
Comment by foofadoooon Aug 25, 2022 8:19am

RE: Switzerland-based biotechnology leader

Eventually, it will be like owning a solid ETF. I view it similar to an ARKK or TSLA....it just requires some long term paitience!   foof
109
Discussion
Post by jw1traderon Aug 24, 2022 12:51pm

Switzerland-based biotechnology leader

portfolio of therapies across a range of disease areas, including treatments for blood disorders, specialized cancers and other rare conditions. With strategic partnerships that include major players ...more  
247
Discussion
Post by Lisaslabon Aug 24, 2022 12:44pm

$4 billion CRISPR is a Switzerland-based biotechnology

biotechnology leader known for its cutting-edge platform to support gene editing and related development of genomic DNA medicines. It has a portfolio of therapies across a range of disease areas ...more  
169
Comment by foofadoooon Aug 19, 2021 7:25am

RE:regrets

IMHO.....it's not to late there will br many growth stocks springboard off CRSPR....CRBU... is a good example... foof
133
Discussion
Post by phred7on Dec 10, 2020 12:56am

regrets

I have been following this and 2 other CRISPR stocks for over 4 years... wow  did I make a mistake. I did not buy. This is a health care  bite me stock.  I wish I had the 20/20 when the ...more  
498
Discussion
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities